Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2007

AstraZeneca Pays $150M for Arrow Therapeutics to Enhance Anti-Infective Pipeline

  • AstraZeneca is strengthening its anti-infective portfolio through a $150-million acquisition of Arrow Therapeutics. "Arrow Therapeutics is an excellent opportunity to acquire a world-class antiviral capability to add to our own anti-bacterial research capabilities and promising early-stage compounds," remarks John Patterson, executive director, development, AstraZeneca.

    Arrow Therapeutics’ antiviral pipeline includes several different approaches toward hepatitis C virus (HCV) and respiratory syncytial virus (RSV). It’s most advanced candidate is in Phase II. RSV604, partnered with Novartis, is a first-in-class, small molecule, oral anti-RSV compound. The company also has two anti-HCV compounds that both target the NS5a protein, including one in Phase I.

    AstraZeneca expects to close this transaction early in 2007. It plans for Arrow Therapeutics to become a hub for anti-viral discovery activities remaining at its present central London site that has 57 employees.

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »